Competitive PressuresThe recent approval of Zepbound for the treatment of moderate-to-severe OSA in patients with obesity may cause potential patients for INSP implants to delay or forego the procedure.
Initial Product LaunchFew Inspire V U.S. procedures have been performed to-date, and reimbursement details were sparse, raising concerns that V's launch is off to a slow start.
Leadership StabilityThe departure of Chief Medical Officer Dr. Charisse Sparks may introduce uncertainty in leadership stability and strategic direction.